Hypoglycaemic and hypolipidaemic effects of fractions from kolaviron, a biflavonoid complex from Garcinia Kola in streptozotocin-induced diabetes mellitus rats.
In the search for natural hypoglycaemic agents as alternatives to synthetic ones that are expensive and not easily accessible, and to justify the use of Garcinia kola seeds in traditional African medicine to treat diabetes, the hypoglycaemic and hypolipidaemic effects of fractions from kolaviron (KV) (a Garcinia kola seed extract) were investigated in normal and streptozotocin (STZ)-diabetic rats. KV, a biflavonoid complex from Garcinia kola seed, was separated by thin-layer chromatography into three fractions; Fraction I (FI), Fraction II (FII) and Fraction III (FIII) with RF values of 0.48, 0.71 and 0.76, respectively. In normoglycaemic rats, KV, FI and FII administered at a dose of 100 mg kg(-1) body weight elicited significant (P < 0.05) hypoglycaemic activity within 4 h of oral administration. Precisely, KV, FI and FII decreased blood glucose levels of normoglycaemic rats by 66%, 50% and 61%, respectively, when compared with controls 30 min after oral administration of the extracts. In hyperglycaemic rats, KV, FI and FII significantly (P < 0.05) reduced blood sugar levels in STZ-diabetic rats within 4 h of oral administration. Furthermore, KV alone produced a significant (P < 0.05) anti-diabetic effect from day 3 to day 7 of oral intubation of STZ-diabetic rats. In addition, the extracts showed favourable effect on the plasma lipid profile of STZ-diabetic rats, and also decreased significantly (P < 0.05) the STZ-induced increase in the activity of microsomal glucose-6-phosphatase and lipid peroxidation (LPO) products. This study confirms the anti-diabetic and hypolipidaemic effects of KV in STZ-diabetic rats. These observed effects of KV are attributed to two of its fractions, FI and FII, with RF values of 0.48 and 0.71, respectively.
Adaramoye
O A
OA
Drug Metabolism and Toxicology Unit, Department of Biochemistry, College of Medicine, University of Ibadan, Nigeria. aoadaramoye@yahoo.com
Adeyemi
E O
EO
D000818:Animals; D044946:Biflavonoids / Q000494:pharmacology; D001786:Blood Glucose; D002784:Cholesterol / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D005419:Flavonoids / Q000494:pharmacology*; D029763:Garcinia kola / Q000737:chemistry; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D015227:Lipid Peroxidation; D008297:Male; D016488:Medicine, African Traditional; D008862:Microsomes, Liver / Q000201:enzymology; D010743:Phospholipids / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D014280:Triglycerides / Q000097:blood
D044946:Biflavonoids; D001786:Blood Glucose; D005419:Flavonoids; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D010743:Phospholipids; D014280:Triglycerides; D013311:Streptozocin; D002784:Cholesterol; D005952:Glucose-6-Phosphatase; C045492:kolaviron